Seizure News and Research

Latest Seizure News and Research

First Edition: January 20, 2012

Today's headlines include dispatches detailing how health care played in last night's S.C. GOP presidential primary debate.

20 Jan 2012

Mylan introduces Levetiracetam to treat seizures

Mylan Inc. today announced that its Mylan Institutional business has launched Levetiracetam in Sodium Chloride Injection, 500 mg/100 mL, 1000 mg/100 mL and 1500 mg/100 mL, for intravenous use.

19 Jan 2012

Chemical preservative in cosmetics can interrupt neurological development

Scientists, health officials, and manufacturers already know that a chemical preservative found in some products, including cosmetics, is harmful to people and animals in high concentrations, but a new Brown University study in tadpoles reports that it can also interrupt neurological development even in very low concentrations.

11 Jan 2012

Doctors may need to adjust seizure drug doses for people with HIV/AIDS: New AAN guideline

A new guideline issued by the American Academy of Neurology recommends doctors use caution when choosing seizure drugs for people with HIV/AIDS to avoid potential drug interactions.

5 Jan 2012

Lundbeck announces availability of ONFI Tablets in the U.S.

Lundbeck announced today that ONFI Tablets are now available for prescribing in the United States. The FDA recently approved ONFI for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years and older.

4 Jan 2012

FDA approves Cyberonics re-designed AspireHC generator

Cyberonics, Inc. today announced that the United States Food and Drug Administration (FDA) has approved its re-designed AspireHC (High Capacity) generator, which was the subject of a voluntary product withdrawal in August 2011.

4 Jan 2012

Similar sounding drug names should come with warnings

There have been mix ups and medication errors with similar sounding names of drugs - eye drops called Durezol and salicylic acid-containing wart remedy Duresal for example.

1 Jan 2012

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB today announced the start of the EXXELERATE study which will evaluate the short- and long-term efficacy of Cimzia (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira(adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this study confirms previously announced plans.

21 Dec 2011

FDA warnings to gastric banding centers

The Food and Drugs Administration (FDA) has come out with warning letters to eight California healthcare organizations and one marketing firm for failing to provide adequate risk information in their advertisements for an implanted gastric band.

14 Dec 2011

Nearly half of children with epilepsy experience adverse events due to invasive EEG

Some type of adverse event occurs in nearly half of children with severe epilepsy undergoing invasive electroencephalography (EEG) recordings, reports a study in the December issue of Operative Neurosurgery, a quarterly supplement to Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

14 Dec 2011

New method for detailed analyses of electrical activity in brain

Researchers at the Norwegian University of Life Sciences (UMB) and Forschungszentrum J-lich in Germany have developed a new method for detailed analyses of electrical activity in the brain.

12 Dec 2011

CSL partners with NIH to study Cytomegalovirus, a common cause of abnormalities in newborns

CSL Limited announced today that it is partnering with the world’s largest health research agency, the US National Institutes of Health (NIH), to study a potential new treatment for the prevention of congenital CMV infection, one of the most common known causes of congenital (i.e., present at birth) abnormalities in the developed world.

7 Dec 2011

Health Alliance, Bayer sign outcomes-based contract to support MS patients

Bayer HealthCare and Health Alliance Medical Plans have entered into an outcomes-based contract for people with relapsing-remitting multiple sclerosis (MS) who are taking Betaseron (interferon beta-1b) to reduce the frequency of clinical exacerbations.

7 Dec 2011

Positive final results from BioLineRx BL-1021 Phase Ia study for neuropathic pain

BioLineRx announced today the final results of the Phase Ia study of BL-1021, an orally available small molecule for neuropathic pain.

6 Dec 2011

DD and autism screening should be routine for all children seen in epilepsy clinics

Research presented today at the American Epilepsy Society's 65th annual meeting suggests that systematic screening for developmental delay (DD) and autism should be routine for all children seen in epilepsy clinics.

6 Dec 2011

Epilepsy in children with ASD is photosensitive: Study

Epilepsy is common in children with autism spectrum disorders (ASD). A new study indicates their epilepsy is surprisingly photosensitive as well. Since photosensitive epilepsies can be triggered by flickering lights, the self-stimulatory behavior of ASD children, such as hand flapping in front of the face, has the potential to dramatically increase the risk of inducing photosensitive seizures.

6 Dec 2011

Prenatal exposure to valproate may increase risk of autism in children

Investigators in a population-based study in Denmark reporting today at the American Epilepsy Society's 65th annual meeting have found there is an increased risk of autism spectrum disorder and childhood autism in children born of mothers who are exposed to the anticonvulsant valproate during pregnancy.

6 Dec 2011

Fetal exposure to valproate impairs IQ till age six

Researchers in the U.S. and U.K. are conducting an ongoing investigation of the cognitive effect of fetal exposure across four commonly used antiepileptic drugs (AEDs) as part of an NIH-funded Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) Study. An early NEAD analysis found that fetal exposure to valproate impairs IQ at age three.

6 Dec 2011

Converting patients to lamotrigine extended-release for epilepsy treatment found effective and safe

Epilepsy drug-switching study shows that using more ethical control groups could be the way forward for testing both drug efficacy and safety

5 Dec 2011

Scientists discover new candidate gene for Dravet syndrome

Dravet syndrome is a severe genetic epilepsy that appears early in life. About 75 percent of cases can be attributed to mutations in the SCN1A gene encoding the sodium channel NaV1.1. The remaining patients with this syndrome are without a definitive molecular genetic diagnosis. Research presented today at the American Epilepsy Society's 65th Annual Meeting has found a non-SCN1A candidate gene and suggests that Dravet syndrome may be caused by any one of a number of yet unidentified genes.

5 Dec 2011

Seizure News and Research

Latest Seizure News and Research

First Edition: January 20, 2012

Mylan introduces Levetiracetam to treat seizures

Chemical preservative in cosmetics can interrupt neurological development

Doctors may need to adjust seizure drug doses for people with HIV/AIDS: New AAN guideline

Lundbeck announces availability of ONFI Tablets in the U.S.

FDA approves Cyberonics re-designed AspireHC generator

Similar sounding drug names should come with warnings

UCB initiates EXXELERATE study in rheumatoid arthritis

FDA warnings to gastric banding centers

Nearly half of children with epilepsy experience adverse events due to invasive EEG

New method for detailed analyses of electrical activity in brain

CSL partners with NIH to study Cytomegalovirus, a common cause of abnormalities in newborns

Health Alliance, Bayer sign outcomes-based contract to support MS patients

Positive final results from BioLineRx BL-1021 Phase Ia study for neuropathic pain

DD and autism screening should be routine for all children seen in epilepsy clinics

Epilepsy in children with ASD is photosensitive: Study

Prenatal exposure to valproate may increase risk of autism in children

Fetal exposure to valproate impairs IQ till age six

Converting patients to lamotrigine extended-release for epilepsy treatment found effective and safe

Scientists discover new candidate gene for Dravet syndrome

Everything you need to know about epilepsy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Seizure News and Research

Latest Seizure News and Research

Everything you need to know about epilepsy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in